Related Experiment Videos
Appropriate Use Criteria for Bone Scintigraphy in Prostate and Breast Cancer: Summary and Excerpts
Kevin J Donohoe1, Erica J Cohen1, Francesco Giammarile2
1Society of Nuclear Medicine and Molecular Imaging.
Abstract
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Association of Early Same-Day Posttherapy Whole-Body SPECT/CT Using Visual RECIP 1.0 with Overall Survival During [177Lu]Lu-PSMA-617 Therapy for Metastatic Castration-Resistant Prostate Cancer.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026
From uncertainty to clarity: The evolution of Nuclear Medicine towards precision theranostics and AI-driven digital twins.
Hellenic journal of nuclear medicine·2026
Building Expertise Across Borders: The IAEA's Expanding Digital Education in Nuclear Medicine and Radiology.
Diagnostics (Basel, Switzerland)·2026
NCCN Guidelines® Insights: Prostate Cancer, Version 5.2026.
Journal of the National Comprehensive Cancer Network : JNCCN·2026
Are Urooncologists Onboard?
Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026
Radiopharmaceutical Therapy-Linked Tumor Resistance: Immune Evasion, Nonimmune Mechanisms, and Immunometabolic Vulnerabilities.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026
Dosimetry-Driven Personalization of Radiopharmaceutical Therapies: Evidence and Opportunities.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026
Pivotal Phase 3 Theranostic Trials: Future Indications.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026
Radiopharmaceutical Combination Therapies in Advanced Prostate Cancer.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026
The Case for Nuclear Oncology Specialization: Training Physicians for Radiopharmaceutical Therapy.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026
Gradient Boosting Machine-Based Prognostic Model with SurvSHAP Analysis for Predicting Secondary Loss of Response to Infliximab Therapy in Crohn's Disease.
Drug design, development and therapy·2026
PCBP2 facilitates miR-93-5p-mediated repression of GDF11 in HCC cell lines.
Molecular therapy. Nucleic acids·2026
miRNA-34a-5p is a novel biomarker and modulator of the radioresponse in esophageal adenocarcinoma.
Molecular therapy. Nucleic acids·2026